Clinical Trial Update: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Phase 2]

View source ↗

Summary

Phase 2 trial of docetaxel, cisplatin, and cetuximab (TPC) in palliative treatment for head and neck squamous cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• docetaxel, cisplatin, cetuximab

Snippet

Sponsor: Stanford University | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-12-17